» Articles » PMID: 20201792

The Vpu Protein: New Concepts in Virus Release and CD4 Down-modulation

Overview
Journal Curr HIV Res
Date 2010 Mar 6
PMID 20201792
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Human immunodeficiency virus type 1 (HIV-1) and several simian immunodeficiency viruses (SIV) encode for a transmembrane protein known as Vpu (viral protein U). While one of the smallest of the HIV-1 proteins, it has two important functions within virus-infected cells. The first of these functions is the down-regulation of the CD4 receptor to prevent its interaction with the HIV-1 envelope glycoprotein. Vpu interacts with the CD4 receptor in the rough endoplasmic reticulum (RER), resulting in its re-translocation across the RER and subsequent degradation via the proteasomal pathway. The second major function of the Vpu protein is to facilitate release of virus from infected cells. Previous studies have shown that virus release is cell type specific, suggesting that certain cells may express a restriction factor that inhibits virus release in the absence of Vpu. Recently, bone marrow stromal antigen 2 (BST-2/HM1.24/CD317/tetherin) has been identified as this factor. This review will focus on new findings within the last four years on the role of Vpu in CD4 down-regulation and the restriction of virus release from cells. We will relate these findings to virus pathogenesis and propose questions regarding BST-2 as a restriction factor.

Citing Articles

Downregulation of endogenous nectin1 in human keratinocytes by herpes simplex virus 1 glycoprotein D excludes superinfection but does not affect NK cell function.

Kite J, Hill M, Preston N, Rubina A, Kollnberger S, Wang E J Gen Virol. 2024; 105(3).

PMID: 38471041 PMC: 10950026. DOI: 10.1099/jgv.0.001969.


HIV-1 virological synapse formation enhances infection spread by dysregulating Aurora Kinase B.

Bruce J, Park E, Magnano C, Horswill M, Richards A, Potts G PLoS Pathog. 2023; 19(7):e1011492.

PMID: 37459363 PMC: 10374047. DOI: 10.1371/journal.ppat.1011492.


The envelope proteins from SARS-CoV-2 and SARS-CoV potently reduce the infectivity of human immunodeficiency virus type 1 (HIV-1).

Henke W, Waisner H, Arachchige S, Kalamvoki M, Stephens E Retrovirology. 2022; 19(1):25.

PMID: 36403071 PMC: 9675205. DOI: 10.1186/s12977-022-00611-6.


Viroporins: Structure, function, and their role in the life cycle of SARS-CoV-2.

Breitinger U, Farag N, Sticht H, Breitinger H Int J Biochem Cell Biol. 2022; 145:106185.

PMID: 35219876 PMC: 8868010. DOI: 10.1016/j.biocel.2022.106185.


HIV-1 Impairment via UBE3A and HIV-1 Nef Interactions Utilizing the Ubiquitin Proteasome System.

Pyeon D, Rojas V, Price L, Kim S, Meharvan S, Park I Viruses. 2019; 11(12).

PMID: 31783587 PMC: 6950590. DOI: 10.3390/v11121098.


References
1.
Hout D, Gomez L, Pacyniak E, Miller J, Hill M, Stephens E . A single amino acid substitution within the transmembrane domain of the human immunodeficiency virus type 1 Vpu protein renders simian-human immunodeficiency virus (SHIV(KU-1bMC33)) susceptible to rimantadine. Virology. 2006; 348(2):449-61. DOI: 10.1016/j.virol.2005.12.025. View

2.
Barlow K, Ajao A, Clewley J . Characterization of a novel simian immunodeficiency virus (SIVmonNG1) genome sequence from a mona monkey (Cercopithecus mona). J Virol. 2003; 77(12):6879-88. PMC: 156208. DOI: 10.1128/jvi.77.12.6879-6888.2003. View

3.
Ishikawa J, Kaisho T, Tomizawa H, Lee B, Kobune Y, Inazawa J . Molecular cloning and chromosomal mapping of a bone marrow stromal cell surface gene, BST2, that may be involved in pre-B-cell growth. Genomics. 1995; 26(3):527-34. DOI: 10.1016/0888-7543(95)80171-h. View

4.
Bartee E, McCormack A, Fruh K . Quantitative membrane proteomics reveals new cellular targets of viral immune modulators. PLoS Pathog. 2007; 2(10):e107. PMC: 1626102. DOI: 10.1371/journal.ppat.0020107. View

5.
Park S, Opella S . Conformational changes induced by a single amino acid substitution in the trans-membrane domain of Vpu: implications for HIV-1 susceptibility to channel blocking drugs. Protein Sci. 2007; 16(10):2205-15. PMC: 2204142. DOI: 10.1110/ps.073041107. View